Recently Added Drugs
1. Akeega patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12734180 | JANSSEN | NA |
Sep, 2043
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 11, 2026 |
| New Indication(I-980) | Dec 12, 2028 |
Drugs and Companies using ABIRATERONE ACETATE; NIRAPARIB TOSYLATE ingredient
Market Authorisation Date: 11 August, 2023
Treatment: Treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) receiving gonadotropin-releasing hormone (gnrh) agonist or bilateral orchiectomy wherein the cancer is associat...
Dosage: TABLET
More Information on Dosage
AKEEGA family patents
2. Aqneursa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12144792 | INTRABIO | Therapeutic Agents For Neurodegenerative Diseases |
Apr, 2037
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 24, 2029 |
| Orphan Drug Exclusivity(ODE-498) | Sep 24, 2031 |
Drugs and Companies using LEVACETYLLEUCINE ingredient
NCE-1 date: 24 September, 2028
Market Authorisation Date: 24 September, 2024
Treatment: Use of levacteylleucine for treatment of ataxia telangiectasia (a-t)
Dosage: FOR SUSPENSION
More Information on Dosage
AQNEURSA family patents
3. Beizray patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11419842 | ZHUHAI | Neutral pH compositions of Docetaxel and human serum albumin |
May, 2036
(9 years from now) | |
| US12090134 | ZHUHAI | Neutral pH compositions of docetaxel and human serum albumin |
May, 2036
(9 years from now) | |
| US12090135 | ZHUHAI | Neutral pH compositions of docetaxel and human serum albumin |
May, 2036
(9 years from now) | |
Drugs and Companies using DOCETAXEL ingredient
Market Authorisation Date: 10 December, 2025
Treatment: Treatment of head and neck cancer
Dosage: SOLUTION
More Information on Dosage
BEIZRAY family patents
4. Bixlenvo patent expiration
BIXLENVO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9216996 | GILEAD | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections |
Dec, 2033
(7 years from now) | |
| US9732092 | GILEAD | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections |
Dec, 2033
(7 years from now) | |
| US9951043 | GILEAD | Therapeutic compounds |
Feb, 2034
(7 years from now) | |
| US9708342 | GILEAD | Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate |
Jun, 2035
(8 years from now) | |
| US10071985 | GILEAD | Therapeutic compounds |
Aug, 2037
(10 years from now) | |
| US11267799 | GILEAD | Solid forms of an HIV capsid inhibitor |
Aug, 2038
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10385067 | GILEAD | Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate |
Jun, 2035
(8 years from now) | |
| US10654827 | GILEAD | Therapeutic compounds |
Aug, 2037
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2027 |
| New Product(NP) | Aug 27, 2029 |
Drugs and Companies using BICTEGRAVIR SODIUM; LENACAPAVIR SODIUM ingredient
NCE-1 date: 22 December, 2026
Market Authorisation Date: 27 August, 2026
Treatment: Treatment of hiv-1 in adults to replace the current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen
Dosage: TABLET
More Information on Dosage
BIXLENVO family patents
5. Bixlenvo Sunlenca Starter Pack (copackaged) patent expiration
BIXLENVO SUNLENCA STARTER PACK (COPACKAGED)'s oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9216996 | GILEAD | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections |
Dec, 2033
(7 years from now) | |
| US9732092 | GILEAD | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections |
Dec, 2033
(7 years from now) | |
| US9951043 | GILEAD | Therapeutic compounds |
Feb, 2034
(7 years from now) | |
| US9708342 | GILEAD | Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate |
Jun, 2035
(8 years from now) | |
| US10071985 | GILEAD | Therapeutic compounds |
Aug, 2037
(10 years from now) | |
| US11267799 | GILEAD | Solid forms of an HIV capsid inhibitor |
Aug, 2038
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10385067 | GILEAD | Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate |
Jun, 2035
(8 years from now) | |
| US10654827 | GILEAD | Therapeutic compounds |
Aug, 2037
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2027 |
| New Product(NP) | Aug 27, 2029 |
Drugs and Companies using BICTEGRAVIR SODIUM, LENACAPAVIR SODIUM; LENACAPAVIR SODIUM ingredient
NCE-1 date: 22 December, 2026
Market Authorisation Date: 27 August, 2026
Treatment: Treatment of hiv-1 in adults to replace the current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen
Dosage: TABLET
More Information on Dosage
BIXLENVO SUNLENCA STARTER PACK (COPACKAGED) family patents
6. Cypsedo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9517988 | HAISCO | Phenol Derivative And Preparation Method And Use In Medicine Thereof |
May, 2034
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10729666 | HAISCO | Use Of Gabaa Receptor Reinforcing Agent In Preparation Of Sedative And Anesthetic Medicament |
May, 2034
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2031 |
Drugs and Companies using CIPEPOFOL ingredient
NCE-1 date: 27 August, 2030
Market Authorisation Date: 27 August, 2026
Treatment: Inducing general anesthesia in adults undergoing surgery
Dosage: EMULSION
More Information on Dosage
CYPSEDO family patents
7. Dyanavel Xr 10 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12734132 | TRIS | NA |
Sep, 2038
(11 years from now) | |
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 04 November, 2021
Treatment: Method of treating attention deficit hyperactivity disorder
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of DYANAVEL XR 10 before its drug patent expiration?
More Information on Dosage
DYANAVEL XR 10 family patents
8. Dyanavel Xr 15 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12734132 | TRIS | NA |
Sep, 2038
(11 years from now) | |
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 04 November, 2021
Treatment: Method of treating attention deficit hyperactivity disorder
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of DYANAVEL XR 15 before its drug patent expiration?
More Information on Dosage
DYANAVEL XR 15 family patents
9. Dyanavel Xr 20 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12734132 | TRIS | NA |
Sep, 2038
(11 years from now) | |
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 04 November, 2021
Treatment: Method of treating attention deficit hyperactivity disorder
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of DYANAVEL XR 20 before its drug patent expiration?
More Information on Dosage
DYANAVEL XR 20 family patents
10. Dyanavel Xr 5 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12734132 | TRIS | NA |
Sep, 2038
(11 years from now) | |
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 04 November, 2021
Treatment: Method of treating attention deficit hyperactivity disorder
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of DYANAVEL XR 5 before its drug patent expiration?
More Information on Dosage
DYANAVEL XR 5 family patents
11. Etcamah patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10131663 | ASTRAZENECA | Chemical Compounds |
Oct, 2037
(10 years from now) | |
| US10590130 | ASTRAZENECA | Chemical Compounds |
Oct, 2037
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10961241 | ASTRAZENECA | Chemical Compounds |
Oct, 2037
(10 years from now) | |
| US12077530 | ASTRAZENECA | Chemical Compounds |
Oct, 2037
(10 years from now) | |
| US12364689 | ASTRAZENECA | Dosage Regimen For The Treatment Of Cancer |
Sep, 2041
(14 years from now) | |
| US12453729 | ASTRAZENECA | Pharmaceutical Formulations |
Oct, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 04, 2031 |
Drugs and Companies using CAMIZESTRANT ingredient
NCE-1 date: 04 September, 2030
Market Authorisation Date: 04 September, 2026
Treatment: Treatment with a cdk4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) of hr-pos., her2-neg. locally advanced or metastatic breast cancer upon detection of esr1 mutation during aromatase inhibito...
Dosage: TABLET
More Information on Dosage
ETCAMAH family patents
12. Exparel patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12728094 | PACIRA | Manufacturing Of Bupivacaine Multivesicular Liposomes |
Jul, 2044
(17 years from now) | |
| US12728095 | PACIRA | Manufacturing Of Bupivacaine Multivesicular Liposomes |
Jul, 2044
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 28, 2014 |
| New Indication(I-771) | Apr 06, 2021 |
| New Patient Population(NPP) | Mar 22, 2024 |
| New Indication(I-929) | Nov 09, 2026 |
Drugs and Companies using BUPIVACAINE ingredient
Market Authorisation Date: 28 October, 2011
Treatment: Method of treating pain, for example, via infiltration for local analgesia; Or via interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, or adductor canal block for reg...
Dosage: INJECTABLE, LIPOSOMAL
How can I launch a generic of EXPAREL before its drug patent expiration?
More Information on Dosage
EXPAREL family patents
13. Filspari patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12714697 | TRAVERE | Biphenyl Sulfonamide Compounds For The Treatment Of Kidney Diseases Or Disorders |
Oct, 2037
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 17, 2028 |
| New Indication(I-989) | Apr 13, 2029 |
| Orphan Drug Exclusivity(ODE-389) | Feb 17, 2030 |
| Orphan Drug Exclusivity(ODE-493) | Sep 05, 2031 |
Drugs and Companies using SPARSENTAN ingredient
NCE-1 date: 17 February, 2027
Market Authorisation Date: 17 February, 2023
Treatment: Treatment of primary immunoglobulin a nephropathy (igan) in adults at risk for disease progression
Dosage: TABLET
More Information on Dosage
FILSPARI family patents
14. Hyftor patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12740970 | NOBELPHARMA | Rapamycin-Containing Pharmaceutical Composition |
Apr, 2045
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 22, 2025 |
| Orphan Drug Exclusivity(ODE-391) | Mar 22, 2029 |
Drugs and Companies using SIROLIMUS ingredient
Market Authorisation Date: 22 March, 2022
Treatment: NA
Dosage: GEL
More Information on Dosage
HYFTOR family patents
15. Javadin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12721837 | AZURITY | NA |
Jul, 2042
(15 years from now) | |
Drugs and Companies using CLONIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 October, 2025
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
JAVADIN family patents
16. Lamlique patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12605388 | AZURITY | Lamotrigine Salts, Co-Crystals, And Compositions |
Feb, 2045
(18 years from now) | |
Drugs and Companies using LAMOTRIGINE HEMIFUMARATE ingredient
Market Authorisation Date: 25 September, 2026
Treatment: NA
Dosage: SUSPENSION
More Information on Dosage
LAMLIQUE family patents
17. Lisraya patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11197867 | PRIOVANT | Aminopyrimidinyl Compounds |
Aug, 2035
(8 years from now) | |
| US9663526 | PRIOVANT | Aminopyrimidinyl Compounds |
Aug, 2035
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2031 |
Drugs and Companies using BREPOCITINIB TOSYLATE ingredient
NCE-1 date: 27 August, 2030
Market Authorisation Date: 27 August, 2026
Treatment: NA
Dosage: TABLET
More Information on Dosage
LISRAYA family patents
18. Lonsurf patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12728130 | TAIHO | Method For Treating Cancer Patients With Severe Renal Impairment |
Feb, 2037
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 22, 2020 |
| New Indication(I-794) | Feb 22, 2022 |
| Orphan Drug Exclusivity(ODE-229) | Feb 22, 2026 |
Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient
NCE-1 date: 23 September, 2019
Market Authorisation Date: 22 September, 2015
Treatment: Treatment of metastatic gastric or gja in severely renally impaired patients treated with at least two lines of chemotherapy that included a fluoropyrimidine, a platinum, a taxane or irinotecan, and i...
Dosage: TABLET
How can I launch a generic of LONSURF before its drug patent expiration?
More Information on Dosage
LONSURF family patents
19. Lumryz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12728110 | ALKERMES | Modified Release Gamma-Hydroxybutyrate Formulations Having Improved Pharmacokinetics |
Jul, 2037
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 01, 2026 |
| Orphan Drug Exclusivity(ODE-431) | May 01, 2030 |
| Orphan Drug Exclusivity(ODE-494) | Oct 16, 2031 |
Drugs and Companies using SODIUM OXYBATE ingredient
Market Authorisation Date: 01 May, 2023
Treatment: NA
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
LUMRYZ family patents
20. Mimrylo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10030061 | TAKEDA AM | Hepcidin Analogues And Uses Thereof |
Mar, 2034
(7 years from now) | |
| US10442846 | TAKEDA AM | Hepcidin Analogues And Uses Thereof |
Mar, 2034
(7 years from now) | |
| US10501515 | TAKEDA AM | Hepcidin Analogues And Uses Thereof |
Mar, 2034
(7 years from now) | |
| US9822157 | TAKEDA AM | Hepcidin Analogues And Uses Thereof |
Mar, 2034
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11807674 | TAKEDA AM | Hepcidin Analogues And Uses Thereof |
Mar, 2034
(7 years from now) | |
| US12269856 | TAKEDA AM | Hepcidin Analogues And Uses Thereof |
Mar, 2034
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 28, 2031 |
Drugs and Companies using RUSFERTIDE ACETATE ingredient
NCE-1 date: 28 August, 2030
Market Authorisation Date: 28 August, 2026
Treatment: Treatment of erythrocytosis in adults with polycythemia vera (pv)
Dosage: POWDER
More Information on Dosage
MIMRYLO family patents
21. Norepinephrine Bitartrate In 5% Dextrose patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12714681 | BAXTER | Packaged, Sealed Container System For Stable Storage Of An Oxygen Sensitive Pharmaceutical Formulation |
Mar, 2041
(14 years from now) | |
Drugs and Companies using NOREPINEPHRINE BITARTRATE ingredient
Market Authorisation Date: 06 February, 2026
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE before its drug patent expiration?
More Information on Dosage
NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE family patents
22. Omcazio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12064430 | HANDA ONCOL | Kinase Inhibitor Salts And Compositions Thereof |
Jun, 2039
(12 years from now) | |
| US12415784 | HANDA ONCOL | Cabozantinib Compositions And Methods Of Use |
Jan, 2044
(17 years from now) | |
| US12516025 | HANDA ONCOL | Cabozantinib Compositions And Methods Of Use |
Jan, 2044
(17 years from now) | |
| US12552567 | HANDA ONCOL | Method For Packaging Articles In Boxes And Packaging Device Operating According To Such A Method |
Jan, 2044
(17 years from now) | |
| US12552749 | HANDA ONCOL | Cabozantinib Compositions And Methods Of Use |
Jan, 2044
(17 years from now) | |
| US12741938 | HANDA ONCOL | Cabozantinib Compositions And Methods Of Use |
Jan, 2044
(17 years from now) | |
Drugs and Companies using CABOZANTINIB LAURYLSULFATE ingredient
Market Authorisation Date: 03 September, 2026
Treatment: Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; Treatment of previously treated, unresectable, locally advanced or metastatic, well-different...
Dosage: CAPSULE
More Information on Dosage
OMCAZIO family patents
23. Oxlumo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12723247 | ALNYLAM | Methods For Inhibition Of Hao1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression |
May, 2041
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-901) | Oct 06, 2025 |
| New Chemical Entity Exclusivity(NCE) | Nov 23, 2025 |
| Orphan Drug Exclusivity(ODE-339) | Nov 23, 2027 |
| Orphan Drug Exclusivity(ODE-415) | Oct 06, 2029 |
Drugs and Companies using LUMASIRAN SODIUM ingredient
NCE-1 date: 23 November, 2024
Market Authorisation Date: 23 November, 2020
Treatment: Treatment of primary hyperoxaluria type 1 (ph1)
Dosage: SOLUTION
More Information on Dosage
OXLUMO family patents
24. Pokonza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12728138 | GENUS | NA |
Mar, 2039
(12 years from now) | |
Drugs and Companies using POTASSIUM CHLORIDE ingredient
Market Authorisation Date: 25 November, 2025
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
POKONZA family patents
25. Ponvory patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12728116 | VANDA | Methods Of Treating Multiple Sclerosis |
Dec, 2044
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 18, 2026 |
Drugs and Companies using PONESIMOD ingredient
NCE-1 date: 18 March, 2025
Market Authorisation Date: 18 March, 2021
Treatment: Treatment of relapsing forms of early-stage multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
Dosage: TABLET
More Information on Dosage
PONVORY family patents
26. Potassium Chloride patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12728138 | GENUS | NA |
Mar, 2039
(12 years from now) | |
Drugs and Companies using POTASSIUM CHLORIDE ingredient
Market Authorisation Date: 25 November, 2025
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
POTASSIUM CHLORIDE family patents
27. Purified Cortrophin Gel patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12734217 | ANI PHARMA | NA |
Oct, 2043
(17 years from now) | |
Drugs and Companies using CORTICOTROPIN ingredient
Market Authorisation Date: 01 January, 1982
Treatment: Allergic conjunctivitis
Dosage: INJECTABLE
More Information on Dosage
PURIFIED CORTROPHIN GEL family patents
28. Qfitlia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE50996 | GENZYME | NA |
Mar, 2033
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 28, 2030 |
| Orphan Drug Exclusivity(ODE-510) | Mar 28, 2032 |
| Orphan Drug Exclusivity(ODE-511) | Mar 28, 2032 |
Drugs and Companies using FITUSIRAN SODIUM ingredient
NCE-1 date: 28 March, 2029
Market Authorisation Date: 28 March, 2025
Treatment: Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with hemophilia a or b with or without factor viii or ix inhibitors
Dosage: SOLUTION
More Information on Dosage
QFITLIA family patents
29. Rasonque patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12403196 | REVOLUTION MEDICINES | Ras Inhibitors |
Sep, 2041
(14 years from now) | |
| US12280113 | REVOLUTION MEDICINES | Ras Inhibitors |
Jan, 2042
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 26, 2031 |
Drugs and Companies using DARAXONRASIB ingredient
NCE-1 date: 26 August, 2030
Market Authorisation Date: 26 August, 2026
Treatment: NA
Dosage: TABLET
More Information on Dosage
RASONQUE family patents
30. Rizafilm patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9301948 | GENSCO | Instantly wettable oral film dosage form without surfactant or polyalcohol |
Jul, 2034
(7 years from now) | |
Drugs and Companies using RIZATRIPTAN BENZOATE ingredient
Market Authorisation Date: 26 February, 2026
Treatment: NA
Dosage: FILM
More Information on Dosage
RIZAFILM family patents
31. Ryzumvi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12721810 | FAMYGEN LIFE SCI | NA |
Jan, 2034
(7 years from now) | |
| US12734126 | FAMYGEN LIFE SCI | NA |
Jan, 2034
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 25, 2026 |
Drugs and Companies using PHENTOLAMINE MESYLATE ingredient
Market Authorisation Date: 25 September, 2023
Treatment: A method of pupil reduction
Dosage: SOLUTION
How can I launch a generic of RYZUMVI before its drug patent expiration?
More Information on Dosage
RYZUMVI family patents
32. Sotalol Hydrochloride patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12740947 | ALTATHERA | Method Of Initiating Sotalol Hydrochloride Dosing |
Aug, 2038
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jul 02, 2016 |
Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient
Market Authorisation Date: 02 July, 2009
Treatment: Dosing regimen for intravenous sotalol for administration in a facility that can provide continuous electrocardiographic monitoring and cardiac resuscitation
Dosage: SOLUTION
More Information on Dosage
SOTALOL HYDROCHLORIDE family patents
33. Sotyktu patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12734169 | BRISTOL | NA |
Sep, 2040
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 09, 2027 |
| New Indication(I-986) | Mar 06, 2029 |
Drugs and Companies using DEUCRAVACITINIB ingredient
NCE-1 date: 09 September, 2026
Market Authorisation Date: 09 September, 2022
Treatment: Treatment of active psoriatic arthritis in adults
Dosage: TABLET
More Information on Dosage
SOTYKTU family patents
34. Tadliq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12734175 | CMP DEV | NA |
Dec, 2038
(12 years from now) | |
Drugs and Companies using TADALAFIL ingredient
Market Authorisation Date: 17 June, 2022
Treatment: NA
Dosage: SUSPENSION
How can I launch a generic of TADLIQ before its drug patent expiration?
More Information on Dosage
TADLIQ family patents
35. Zanvastro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11786546 | IONIS | Compounds And Methods For Modulating Gfap |
May, 2041
(14 years from now) | |
Drugs and Companies using ZILGANERSEN SODIUM ingredient
Market Authorisation Date: 03 September, 2026
Treatment: Use in the treatment of alexander disease in pediatric and adult patients
Dosage: SOLUTION
More Information on Dosage
ZANVASTRO family patents
36. Zenbexus patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9828361 | BRISTOL MYERS | Arylmethoxy Isoindoline Derivatives And Compositions Comprising And Methods Of Using The Same |
Feb, 2031
(4 years from now) | |
| US8518972 | BRISTOL MYERS | Arylmethoxy Isoindoline Derivatives And Compositions Comprising And Methods Of Using The Same |
Jun, 2031
(4 years from now) | |
| US9221788 | BRISTOL MYERS | Salts And Solid Forms Of (S)-3-(4- (4-(Morpholinomethyl)Benzyl)Oxy)-1-Oxoisoindolin-2-Yl)Piperidine-2,6-Dione And Compositions Comprising And Methods Of Using The Same |
Sep, 2033
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9629849 | BRISTOL MYERS | Salts And Solid Forms Of (S)-3-(4-((4-(Morpholinomethyl)Benzyl)Oxy)-1-Oxoisoindolin-2-Yl)Piperidine-2,6-Dione And Compositions Comprising And Methods Of Using The Same |
Aug, 2033
(6 years from now) | |
| USRE49647 | BRISTOL MYERS | NA |
Oct, 2034
(7 years from now) | |
| USRE50917 | BRISTOL MYERS | NA |
Oct, 2034
(7 years from now) | |
| US11529339 | BRISTOL MYERS | Combination Therapy For The Treatment Of Cancer |
Sep, 2039
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2031 |
Drugs and Companies using IBERDOMIDE HYDROCHLORIDE ingredient
NCE-1 date: 13 August, 2030
Market Authorisation Date: 13 August, 2026
Treatment: In combination with daratumumab and hyaluronidase-fihj and dexamethasone for treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome...
Dosage: CAPSULE
More Information on Dosage
ZENBEXUS family patents
37. Zoryve patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12697329 | ARCUTIS | NA |
Jun, 2037
(10 years from now) | |
| US12685727 | ARCUTIS | NA |
Jun, 2037
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 15, 2026 |
| New Patient Population(NPP) | Oct 05, 2026 |
| New Strength(NS) | Oct 04, 2028 |
| New Indication(I-969) | May 22, 2028 |
Drugs and Companies using ROFLUMILAST ingredient
Market Authorisation Date: 09 July, 2024
Treatment: Topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age
Dosage: FOAM; CREAM
How can I launch a generic of ZORYVE before its drug patent expiration?
More Information on Dosage
ZORYVE family patents
38. Zusduri patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12740940 | UROGEN | Treatment Of Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer With A Thermally Gelling Pharmaceutical Composition Containing Mitomycin |
Jul, 2044
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 12, 2028 |
Drugs and Companies using MITOMYCIN ingredient
Market Authorisation Date: 12 June, 2025
Treatment: Increasing the probability of maintaining a complete response for at least 15 months following primary chemoablation treatment of recurrent low-grade intermediate-risk non-muscle-invasive bladder canc...
Dosage: POWDER
More Information on Dosage
ZUSDURI family patents